SARS-CoV-2 Variant Spike Protein Trimers

We have and will continue to develop high-quality recombinant purified SARS-CoV-2 trimers for all major variants to date. Check back here for updates as new variants emerge. Order directly or contact us for bulk pricing options.

BR.2.1 (Coming soon!)

CA.3.1

CH.1.1

SARS-CoV-2 Therapeutic mAb Development

Using our rabbit monoclonal antibody discovery platform RabWiz, we developed a potent mAb that showed strong neutralization of the Wuhan-Hu-1 strain. We humanized this antibody and subjected it to our proprietary STEM affinity maturation platform, iteratively improving affinity and broadening neutralization potency on SARS-CoV-2 variants as they emerged. This resulted in the most potent, broadest neutralizing COVID-19 therapeutic mAbs to date.

See our published work, detailing our engineering strategy and assaying antibody potency: Rapid engineering of SARS-CoV-2 therapeutic antibodies to increase breadth of neutralization including XBB.1.5 and BQ.1.1 (preprint).

Next-generation Quantitative COVID-19 Antigen Tests

We have developed high affinity, highly specific rabbit antibodies that can be used in antigen diagnostic tests for active SARS-CoV-2 infections. These antibodies target multiple epitopes within the nucleoprotein (NP) of SARS-CoV-2, allowing for sandwich immunoassay detection compatible with any existing antibody diagnostic methods. The epitopes are also unique to SARS-CoV-2 compared to related coronaviruses, allowing for highly specific detection. These antibodies are available from our catalog in unconjugated or biotinylated format. We are currently developing a lateral flow assay using these antibodies to create a rapid diagnostic test.

Here you can find our catalog of COVID-19 research reagents or our recommended pair of unconjugated and biotinylated antibodies for use in your own assays.